Osteosarcopenia: where osteoporosis and sarcopenia collide
Osteosarcopenia: where osteoporosis and sarcopenia collide
The coexistence of osteoporosis and sarcopenia has been recently considered in some groups as a syndrome termed ‘osteosarcopenia’. Osteoporosis describes low bone mass and deterioration of the micro-architecture of the bone, whereas sarcopenia is the loss of muscle mass, strength and function. With an ageing population the prevalence of both conditions is likely to increase substantially over the coming decades and is associated with significant personal and societal burden. The sequelae for an individual suffering from both conditions together include a greater risk of falls, fractures, institutionalization and mortality. The aetiology of ‘osteosarcopenia’ is multifactorial with several factors linking muscle and bone function, including genetics, age, inflammation and obesity. Several biochemical pathways have been identified that are facilitating the development of several promising therapeutic agents, which target both muscle and bone. In the current review we outline the epidemiology, pathogenesis and clinical consequences of ‘osteosarcopenia’ and explore current and potential future management strategies.
Clynes, Michael
b860d3b7-12ee-42b8-8cd5-1e1abfccbee2
Gregson, Celia L.
30fae822-e733-4e67-b11a-e46dfb1b269a
Bruyere, Olivier
7d127754-d7d6-4328-8f76-212df27727b6
Cooper, Cyrus
e05f5612-b493-4273-9b71-9e0ce32bdad6
Dennison, Elaine
ee647287-edb4-4392-8361-e59fd505b1d1
Clynes, Michael
b860d3b7-12ee-42b8-8cd5-1e1abfccbee2
Gregson, Celia L.
30fae822-e733-4e67-b11a-e46dfb1b269a
Bruyere, Olivier
7d127754-d7d6-4328-8f76-212df27727b6
Cooper, Cyrus
e05f5612-b493-4273-9b71-9e0ce32bdad6
Dennison, Elaine
ee647287-edb4-4392-8361-e59fd505b1d1
Clynes, Michael, Gregson, Celia L., Bruyere, Olivier, Cooper, Cyrus and Dennison, Elaine
(2020)
Osteosarcopenia: where osteoporosis and sarcopenia collide.
Rheumatology.
(doi:10.1093/rheumatology/keaa755).
Abstract
The coexistence of osteoporosis and sarcopenia has been recently considered in some groups as a syndrome termed ‘osteosarcopenia’. Osteoporosis describes low bone mass and deterioration of the micro-architecture of the bone, whereas sarcopenia is the loss of muscle mass, strength and function. With an ageing population the prevalence of both conditions is likely to increase substantially over the coming decades and is associated with significant personal and societal burden. The sequelae for an individual suffering from both conditions together include a greater risk of falls, fractures, institutionalization and mortality. The aetiology of ‘osteosarcopenia’ is multifactorial with several factors linking muscle and bone function, including genetics, age, inflammation and obesity. Several biochemical pathways have been identified that are facilitating the development of several promising therapeutic agents, which target both muscle and bone. In the current review we outline the epidemiology, pathogenesis and clinical consequences of ‘osteosarcopenia’ and explore current and potential future management strategies.
Text
Osteosarcopenia review for submission final after CC modified clean
- Accepted Manuscript
More information
Accepted/In Press date: 2 October 2020
e-pub ahead of print date: 4 December 2020
Identifiers
Local EPrints ID: 445662
URI: http://eprints.soton.ac.uk/id/eprint/445662
ISSN: 1462-0324
PURE UUID: e9a89d9c-71fa-4bab-8d32-8c3f3baf6859
Catalogue record
Date deposited: 05 Jan 2021 17:33
Last modified: 18 Mar 2024 05:06
Export record
Altmetrics
Contributors
Author:
Celia L. Gregson
Author:
Olivier Bruyere
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
